Literature DB >> 26857685

PPAR Agonists: I. Role of Receptor Subunits in Alcohol Consumption in Male and Female Mice.

Yuri A Blednov1, Mendy Black1, Jillian M Benavidez1, Eleni E Stamatakis1, R Adron Harris1.   

Abstract

BACKGROUND: Several peroxisome proliferator-activated receptor (PPAR) agonists reduce voluntary alcohol consumption in rodent models, and evidence suggests that PPARα and γ subunits play an important role in this effect. To define the subunit dependence of this action, we tested selective PPARα and α/γ agonists and antagonists in addition to null mutant mice lacking PPARα.
METHODS: The effects of fenofibrate (PPARα agonist) and tesaglitazar (PPARα/γ agonist) on continuous and intermittent 2-bottle choice drinking tests were examined in male and female wild-type mice and in male mice lacking PPARα. We compared the ability of MK886 (PPARα antagonist) and GW9662 (PPARγ antagonist) to inhibit the effects of fenofibrate and tesaglitazar in wild-type mice. The estrogen receptor antagonist, tamoxifen, can inhibit PPARγ-dependent transcription and was also studied in male and female mice.
RESULTS: Fenofibrate and tesaglitazar reduced ethanol (EtOH) consumption and preference in wild-type mice, but these effects were not observed in mice lacking PPARα. MK886 inhibited the action of fenofibrate, but not tesaglitazer, while GW9662 did not inhibit either agonist. The PPAR agonists were more effective in male mice compared to females, and drinking in the continuous 2-bottle choice test was more sensitive to fenofibrate and tesaglitazar compared to drinking in the intermittent access test. Tamoxifen also reduced EtOH consumption in male mice and this action was inhibited by GW9662, but not MK886, suggesting that it acts by activation of PPARγ.
CONCLUSIONS: Our study using selective PPAR agonists, antagonists, and null mutant mice indicates a key role for PPARα in mediating reduced EtOH consumption by fenofibrate and tesaglitazar.
Copyright © 2016 by the Research Society on Alcoholism.

Entities:  

Keywords:  Fenofibrate; GW9662; MK886; PPARzzm321990α; Tesaglitazar

Mesh:

Substances:

Year:  2016        PMID: 26857685      PMCID: PMC4775296          DOI: 10.1111/acer.12976

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  25 in total

1.  Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.

Authors:  A Michael Lincoff; Jean-Claude Tardif; Gregory G Schwartz; Stephen J Nicholls; Lars Rydén; Bruce Neal; Klas Malmberg; Hans Wedel; John B Buse; Robert R Henry; Arlette Weichert; Ruth Cannata; Anders Svensson; Dietmar Volz; Diederick E Grobbee
Journal:  JAMA       Date:  2014-04-16       Impact factor: 56.272

2.  AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats.

Authors:  Bengt Ljung; Krister Bamberg; Björn Dahllöf; Ann Kjellstedt; Nicholas D Oakes; Jörgen Ostling; Lennart Svensson; Germán Camejo
Journal:  J Lipid Res       Date:  2002-11       Impact factor: 5.922

3.  Estrogen receptor alpha binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor gamma signaling in breast cancer cells.

Authors:  Daniela Bonofiglio; Sabrina Gabriele; Saveria Aquila; Stefania Catalano; Mariaelena Gentile; Emilia Middea; Francesca Giordano; Sebastiano Andò
Journal:  Clin Cancer Res       Date:  2005-09-01       Impact factor: 12.531

4.  PPAR Agonists: II. Fenofibrate and Tesaglitazar Alter Behaviors Related to Voluntary Alcohol Consumption.

Authors:  Yuri A Blednov; Mendy Black; Jillian M Benavidez; Eleni E Stamatakis; R Adron Harris
Journal:  Alcohol Clin Exp Res       Date:  2016-02-09       Impact factor: 3.455

5.  Inhibition of peroxisome-proliferator-activated receptor (PPAR)alpha by MK886.

Authors:  J P Kehrer; S S Biswal; E La; P Thuillier; K Datta; S M Fischer; J P Vanden Heuvel
Journal:  Biochem J       Date:  2001-06-15       Impact factor: 3.857

6.  Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662.

Authors:  Lisa M Leesnitzer; Derek J Parks; Randy K Bledsoe; Jeff E Cobb; Jon L Collins; Thomas G Consler; Roderick G Davis; Emily A Hull-Ryde; James M Lenhard; Lisa Patel; Kelli D Plunket; Jennifer L Shenk; Julie B Stimmel; Christina Therapontos; Timothy M Willson; Steven G Blanchard
Journal:  Biochemistry       Date:  2002-05-28       Impact factor: 3.162

7.  Intermittent access to 20% ethanol induces high ethanol consumption in Long-Evans and Wistar rats.

Authors:  Jeffrey A Simms; Pia Steensland; Brian Medina; Kenneth E Abernathy; L Judson Chandler; Roy Wise; Selena E Bartlett
Journal:  Alcohol Clin Exp Res       Date:  2008-07-30       Impact factor: 3.455

8.  Activation of PPARγ by pioglitazone potentiates the effects of naltrexone on alcohol drinking and relapse in msP rats.

Authors:  Serena Stopponi; Giordano de Guglielmo; Lorenzo Somaini; Andrea Cippitelli; Nazzareno Cannella; Marsida Kallupi; Massimo Ubaldi; Markus Heilig; Gregory Demopulos; George Gaitanaris; Roberto Ciccocioppo
Journal:  Alcohol Clin Exp Res       Date:  2013-03-29       Impact factor: 3.455

9.  Positive relationship between dietary fat, ethanol intake, triglycerides, and hypothalamic peptides: counteraction by lipid-lowering drugs.

Authors:  Jessica R Barson; Olga Karatayev; Guo-Qing Chang; Deanne F Johnson; Miriam E Bocarsly; Bartley G Hoebel; Sarah F Leibowitz
Journal:  Alcohol       Date:  2009-09       Impact factor: 2.405

Review 10.  Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review.

Authors:  Bogna Grygiel-Górniak
Journal:  Nutr J       Date:  2014-02-14       Impact factor: 3.271

View more
  16 in total

1.  The peroxisome proliferator-activated receptor alpha agonist fenofibrate attenuates alcohol self-administration in rats.

Authors:  Colin N Haile; Therese A Kosten
Journal:  Neuropharmacology       Date:  2017-01-11       Impact factor: 5.250

Review 2.  Genes and Alcohol Consumption: Studies with Mutant Mice.

Authors:  J Mayfield; M A Arends; R A Harris; Y A Blednov
Journal:  Int Rev Neurobiol       Date:  2016       Impact factor: 3.230

3.  In vivo interactions between α7 nicotinic acetylcholine receptor and nuclear peroxisome proliferator-activated receptor-α: Implication for nicotine dependence.

Authors:  Asti Jackson; Deniz Bagdas; Pretal P Muldoon; Aron H Lichtman; F Ivy Carroll; Mark Greenwald; Michael F Miles; M Imad Damaj
Journal:  Neuropharmacology       Date:  2017-03-07       Impact factor: 5.250

Review 4.  From gene networks to drugs: systems pharmacology approaches for AUD.

Authors:  Laura B Ferguson; R Adron Harris; Roy Dayne Mayfield
Journal:  Psychopharmacology (Berl)       Date:  2018-03-01       Impact factor: 4.530

5.  Transcriptional Regulators as Targets for Alcohol Pharmacotherapies.

Authors:  Antonia M Savarese; Amy W Lasek
Journal:  Handb Exp Pharmacol       Date:  2018

6.  Effects of Pharmacologically Targeting Neuroimmune Pathways on Alcohol Drinking in Mice Selectively Bred to Drink to Intoxication.

Authors:  Angela R Ozburn; Pamela Metten; Sheena Potretzke; Kayla G Townsley; Yuri A Blednov; John C Crabbe
Journal:  Alcohol Clin Exp Res       Date:  2020-01-13       Impact factor: 3.455

Review 7.  Preclinical Medication Development: New Targets and New Drugs.

Authors:  Chelsea R Kasten; Stephen L Boehm
Journal:  Alcohol Clin Exp Res       Date:  2016-05-14       Impact factor: 3.455

8.  PPAR Agonists: II. Fenofibrate and Tesaglitazar Alter Behaviors Related to Voluntary Alcohol Consumption.

Authors:  Yuri A Blednov; Mendy Black; Jillian M Benavidez; Eleni E Stamatakis; R Adron Harris
Journal:  Alcohol Clin Exp Res       Date:  2016-02-09       Impact factor: 3.455

Review 9.  Inflammatory responses to alcohol in the CNS: nuclear receptors as potential therapeutics for alcohol-induced neuropathologies.

Authors:  Cynthia J M Kane; Paul D Drew
Journal:  J Leukoc Biol       Date:  2016-07-26       Impact factor: 4.962

Review 10.  Medications for alcohol use disorders: An overview.

Authors:  Mohammed Akbar; Mark Egli; Young-Eun Cho; Byoung-Joon Song; Antonio Noronha
Journal:  Pharmacol Ther       Date:  2017-12-02       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.